Objective: Surface-guided radiation therapy (SGRT, AlignRT) was used to analyze motion during stereotactic body radiotherapy (SBRT) in lung cancer patients and to explore the margin of the planning target volume (PTV).
Methods: The residual errors of the AlignRT were evaluated based on grayscale cone-beam computed tomography registration results before each treatment. AlignRT log file was used to analyze the correlation between the frequency and longest duration of errors larger than 2 mm and lasting longer than 2 s and maximum error with age and treatment duration. The displacement value at the end of treatment, the average displacement value, and the 95% probability density displacement interval were defined as intrafraction errors, and PTV1, PTV2, PTV3 were calculated by Van Herk formula or Z score analysis. Organ dosimetric differences were compared after the experience-based margin was replaced with PTV3.
Results: The interfraction residual errors were Vrt , 0.06 ± 0.18 cm; Lng , -0.03 ± 0.19 cm; Lat , 0.02 ± 0.15 cm; Pitch , 0.23 ± 0.7°; Roll , 0.1 ± 0.69°; Rtn , -0.02 ± 0.79°. The frequency, longest duration and maximum error in vertical direction were correlated with treatment duration (r = 0.404, 0.353, 0.283, p < 0.05, respectively). In the longitudinal direction, the frequency was correlated with age and treatment duration (r = 0.376, 0.283, p < 0.05, respectively), maximum error was correlated with age (r = 0.4, P < 0.05). Vertical, longitudinal, lateral margins of PTV1, PTV2, PTV3 were 2 mm, 4 mm, 2 mm; 2 mm, 2 mm, 2 mm, 3 mm, 5 mm, 3 mm, respectively. After replacing the original PTV, mean lung dose (MLD), 2-cm chest wall dose (CD), lung V decreased by 0.2 Gy, 2.1 Gy, 0.5%, respectively (p < 0.05).
Conclusion: AlignRT can be used for interfraction setup and monitoring intrafraction motion. It is more reasonable to use upper and lower limits of the 95% probability density interval as an intrafraction error.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10930008 | PMC |
http://dx.doi.org/10.1002/acm2.14195 | DOI Listing |
Rep Pract Oncol Radiother
December 2024
Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States.
Background: The primary treatment of metastatic spine disease is radiation therapy (RT), traditionally conventional external beam RT (EBRT) or stereotactic body RT (SBRT). Until recently, there had been no Level 1 evidence supporting SBRT over EBRT, which has led to difficulties obtaining insurance approval. Publication of the first randomized controlled trial (RCT) comparing SBRT to EBRT for spine metastases [Canadian Cancer Trials Group (CCTG)] helped change this.
View Article and Find Full Text PDFAdv Radiat Oncol
January 2025
Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Purpose: Despite its high cost-effectiveness, radiation oncology faces the greatest prior authorization (PA) burden of any medical specialty. Insurance denials and resulting treatment delays have been documented across several treatment modalities, including stereotactic body radiation, intensity modulated radiation, and proton therapy. Although insurance companies suggest that PA is intended to control health care spending and ensure the implementation of evidence-based practice, the number of radiation treatment plans reviewed by the PA process that result in changes is quite low.
View Article and Find Full Text PDFCancer Res Treat
December 2024
Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul.
Purpose: To investigate the clinical outcomes of stereotactic body radiation therapy (SBRT) in patients with large uveal melanoma (UM).
Materials And Methods: We conducted a retrospective review of 64 consecutive patients with UM treated with Cyberknife at Yonsei Cancer Center from September 2015 to October 2021. The median radiation dose was 60 Gy (range 48-64 Gy) administered in four fractions every alternate day.
Clin Oncol (R Coll Radiol)
December 2024
Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, UK; Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, London, UK.
Aims: Oligometastatic disease describes limited metastases amenable to therapy such as stereotactic body radiotherapy (SBRT). This study aims to understand which outcomes are most important to patients when considering SBRT as a treatment option. The insights gained will help inform future patient-directed trial endpoints and provide valuable guidance to clinicians supporting patients through their decision-making process.
View Article and Find Full Text PDFPhys Med
January 2025
Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Background And Purpose: Free-breathing computed tomography (FBCT) used in treatment planning for lower thoracic (Th8-Th12) spine stereotactic body radiotherapy (SBRT) can cause deviations between planned and irradiated doses due to diaphragm movement (DM). This study analyzed the dosimetric impact of DM on lower thoracic spine SBRT.
Materials And Methods: Data were collected from 19 patients who underwent FBCT and four-dimensional CT (4DCT) during the same session.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!